Skip to main content

Funding and public record

Source linked non-dilutive project support

NEUVIOR has been selected for non-dilutive support for defined project work. Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome.

See NEUVIOR’s current product priorityRead the coverage
Public record | Project level sourcesPublic presentation | Project level onlyThird party record | SMART:SCOTLAND support

The first ten month record

Early support should shorten the distance to useful proof.

NEUVIOR has been selected for non-dilutive support for defined project work.

Grant support is useful when it funds defined learning and capability: product architecture, feasibility work, technical evidence, commercial evaluation and the next decision. It should not be confused with customer revenue, investment capital, product approval or market adoption.

Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome.

01

Project level record

Each already-public project keeps its own source, provider, published award value and status. No aggregate total is presented here.

Evidence structure
02

First ten months

The period in which NEUVIOR was selected for the defined innovation support.

Selection period
03

One obligation

Turn the support into stronger evidence, better execution and a more valuable company.

What happens next

Published project records

Read each disclosed award on its own terms.

The public record identifies VIONIX ZERO, PHARMORIS and publicly reported SMART:SCOTLAND support. The first two link to UKRI project records; SMART:SCOTLAND links to dated third-party coverage.

An ‘up to’ figure is a maximum grant-award ceiling. It is not the eligible project cost, company contribution or cash received.

Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome.

Open UKRI project 10180575Open UKRI project 10173524Open the classified SMART:SCOTLAND recordRead the evidence boundary
01

£25,000

VIONIX ZERO

Innovate UK grant award
02

£49,928

PHARMORIS

Innovate UK grant award
03

Publicly reported support

Scottish Enterprise SMART:SCOTLAND

Dated third-party coverage
04

No aggregate claim

Public disclosure stays at project level so award ceilings, eligible project costs, company contributions and cash received are not combined into one misleading figure.

Evidence boundary

How to read the record

Award ceilings, project costs, contributions and cash are different facts.

A grant offer defines the maximum eligible support available under agreed terms. Payment may follow eligible costs, evidence and programme milestones over time. Customer revenue is separate again, because it shows whether a buyer chose to pay for a product or service.

Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome.

See the investor thesisRead the full media record
Human decision requiredProceed only inside an evidenced and governed scope.
01

Maximum award ceiling

The maximum grant support available under an award, subject to its terms and evidence requirements.

02

Funds drawn

Money actually remitted against the programme’s evidence and payment process at a point in time.

03

Revenue and adoption

Commercial evidence created when a customer contracts, pays and uses a product or service within an agreed scope.

Classified public record

Review the complete public record

OPPORTUNITY + PUBLIC EVIDENCE

Read the opportunity. Then inspect the evidence.

The analysis explains why the medicines opportunity matters. The public record shows dated support and publication, not revenue, product adoption or realised value.

  1. NEUVIOR Founder ReflectionsNEUVIOR analysis

    What feasibility support should actually buy

    Support matters when it converts expensive uncertainty into a clearer product, technical, commercial or stop decision.

    See what early support should actually buy
  2. NEUVIOR InsightsNEUVIOR analysis

    NHS digital programmes do not fail on dashboards. They fail on deployment

    The NHS does not lack medicines dashboards. It lacks enough tools that turn those signals into action. That distinction matters because many digital programmes in medicines still behave as though visibility is the scarce resource.

    Understand the implementation gap
  3. TheBusinessDesk.comRelease derived reporting

    NEUVIOR company support coverage

    Scottish regional business coverage recording publicly reported SMART:SCOTLAND support for NEUVIOR.

    Open the classified Scottish company record
Explore the medicines case

NEUVIOR Insights and After Publication reflections are company or founder analysis. Publisher records evidence publication, not endorsement, adoption, product readiness, savings or clinical outcomes.

Make the next step useful

Bring the problem that needs a clearer decision.

Tell us what is stuck, what decision you need to make and what a better outcome would change. We will connect you to the most relevant NEUVIOR, PHARMORIS, media or investor route.

See NEUVIOR’s current product prioritySpeak with NEUVIOR

QUESTIONS · ANSWERED DIRECTLY

The useful answers, in one place.

Browse every question
01What non-dilutive support has NEUVIOR been selected for?

NEUVIOR has been selected for non-dilutive support for defined project work. The public record links to the published project level sources without presenting an aggregate total.

02Does a published award value mean all cash has been received?

No. Published award records are source linked. Award ceilings, eligible project costs, company contributions and cash received are different figures; none is customer revenue, equity raised, adoption or an outcome.

03Why does NEUVIOR not publish one aggregate support figure?

A single total can mix award ceilings, eligible project costs, company contributions and cash received. NEUVIOR therefore links the already public project records and keeps those definitions separate.

04Does grant support prove adoption or approval?

No. A grant award supports defined innovation work. It does not itself prove a product is deployed, approved, commercially adopted or delivering an outcome.